Results 31 to 40 of about 5,637 (227)

Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells [PDF]

Journal of General Virology, 2017
Joseph P Dougherty
exaly   +2 more sources

HIV-1 latency reversal agent boosting is not limited by opioid use

JCI Insight, 2023
Abstract The opioid epidemic may impact the HIV-1 reservoir and its reversal from latency in virally suppressed people with HIV (PWH). We studied forty-seven PWH and observed that lowering the concentration of HIV-1 latency reversal agents (LRA), used in combination with small molecules that do not reverse latency ...
Tyler Lilie, Jennifer Bouzy, Archana Asundi, Jessica Taylor, Samantha Roche, Alex Olson, Kendyll Coxen, Heather Corry, Hannah Jordan, Kiera Clayton, Nina Lin, Athe Tsibris   +11 more
openaire   +3 more sources

HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency

Frontiers in Microbiology, 2018
Latently infected T lymphocytes are an important barrier toward eliminating a persistent HIV infection. Here we describe an HIV-based recombinant fluorescent-lentivirus referred to as “rfl-HIV” that enables to analyze sense and antisense transcription by
Mie Kobayashi-Ishihara, Mie Kobayashi-Ishihara, Kazutaka Terahara, Javier P. Martinez, Makoto Yamagishi, Ryutaro Iwabuchi, Ryutaro Iwabuchi, Christian Brander, Christian Brander, Christian Brander, Manabu Ato, Manabu Ato, Toshiki Watanabe, Andreas Meyerhans, Andreas Meyerhans, Yasuko Tsunetsugu-Yokota, Yasuko Tsunetsugu-Yokota, Yasuko Tsunetsugu-Yokota   +17 more
doaj   +1 more source

TLR7 Agonist GS–9620 Combined with Nicotinamide Generate Viral Reactivation in Seronegative SHIV_SF162P3-Infected Rhesus Monkeys

Biomedicines, 2023
Antiretroviral therapy is capable of inhibiting HIV replication, but it fails to completely achieve a cure due to HIV persistence. The commonly used HIV cure approach is the “shock and kill” strategy, which employs latency-reversing agents to trigger ...
Zhe Cong, Yuting Sun, Cui Dang, Chenbo Yang, Jingjing Zhang, Jiahan Lu, Ting Chen, Qiang Wei, Wei Wang, Jing Xue   +9 more
doaj   +1 more source

Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells

eLife, 2018
Human immunodeficiency virus (HIV) infection is currently incurable, due to the persistence of latently infected cells. The ‘shock and kill’ approach to a cure proposes to eliminate this reservoir via transcriptional activation of latent proviruses ...
Emilie Battivelli, Matthew S Dahabieh, Mohamed Abdel-Mohsen, J Peter Svensson, Israel Tojal Da Silva, Lillian B Cohn, Andrea Gramatica, Steven Deeks, Warner C Greene, Satish K Pillai, Eric Verdin   +10 more
doaj   +1 more source

Coloring hidden viruses

eLife, 2018
An improved dual-color reporter reveals how the fate of latent HIV-1 depends on where it integrates in the human genome.
Marina Lusic
doaj   +1 more source

Pathways towards human immunodeficiency virus elimination

EBioMedicine, 2020
Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents.
Prasanta K. Dash, Bhavesh D. Kevadiya, Hang Su, Mary G. Banoub, Howard E. Gendelman   +4 more
doaj   +1 more source

The role of latency reversal agents in the cure of HIV: A review of current data [PDF]

Immunology Letters, 2018
The definitive cure for human immunodeficiency virus type-1 (HIV) infection is represented by the eradication of the virus from the patient's body. To reach this result, cells that are infected but do not produce the virus must become recognizable to be killed by the immune system.
Bashiri, Kiandokht, Rezaei, Nima, Nasi, Milena, Cossarizza, Andrea   +3 more
openaire   +3 more sources

Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity.MethodsA population pharmacokinetic analysis was performed in 15 HIV-1-infected patients who ...
José Moltó, Miriam Rosás-Umbert, Cristina Miranda, Christian Manzardo, Maria C Puertas, Marta Ruiz-Riol, Miriam López, Jose M Miró, Javier Martinez-Picado, Bonaventura Clotet, Christian Brander, Beatriz Mothe, Marta Valle   +12 more
openaire   +3 more sources

Engineering CAR T Cells to Target the HIV Reservoir

Frontiers in Cellular and Infection Microbiology, 2020
The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that ...
Wenli Mu, Mayra A. Carrillo, Scott G. Kitchen   +2 more
doaj   +1 more source